Benitec Biopharma Net Income

The latest net income for BNTC is $-49M as of March 2026. That compares with $-26M in the prior-year period — down 84.5% year over year. That is below the sector sector average of $96M. Investors often review this figure alongside Benitec Biopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, BNTC's net income moved from $-26M to $-49M — a 84.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Benitec Biopharma's operating scale or balance-sheet position.

Against its sector companies, BNTC currently prints $-49M for net income, while the sector average sits near $96M. That is roughly 150.8% below the sector mean. Large gaps often invite a closer look at Benitec Biopharma's growth, margins, and balance sheet.

A net income figure of $-49M for BNTC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $96M. Explore the charts below for those layers of context.

After noting BNTC's net income ($-49M), review year-over-year change from $-26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.